Want to see JP:4576 full AI Analyst Report?
D.Western Therapeutics Institute (4576) AI Stock Analysis
D.Western Therapeutics Institute
(TSE/TYO:4576)
The score is held down primarily by sustained losses and ongoing negative free cash flow (cash burn), despite improving loss trends and strong gross margins. Technicals also weigh on the score as the stock trades well below major moving averages with very weak momentum. Valuation provides limited support because the company is unprofitable and no dividend yield is available.
D.Western Therapeutics Institute (4576) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 3.40B
- Dividend Yield
- ―
- Average Volume (3M)
- 298.71K
- Price to Earnings (P/E)
- -5.0
- Beta (1Y)
- -0.18
- Revenue Growth
- -41.25%
- EPS Growth
- 55.11%
- Country
- Japan
- Employees
- 19
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
D.Western Therapeutics Institute Business Overview & Revenue Model
Company Description
D. Western Therapeutics Institute, Inc. is a biotechnology enterprise focused on the research, discovery, and innovation of various pharmaceutical drugs. The company's current portfolio includes GLANATEC and GLA-ALPHA, ophthalmic solutions prescribed...
D.Western Therapeutics Institute Financial Statement Overview
Summary
Financials remain weak overall: profitability is deeply negative with net losses still exceeding revenue, and cash flow is consistently negative (ongoing cash burn). Positives include very strong gross margins and meaningfully narrowing losses in 2025, plus improved leverage (debt-to-equity ~0.42) supporting a somewhat healthier balance sheet.
Income Statement
32NegativeBalance Sheet
58NeutralCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 305.74M | 387.62M | 471.58M | 428.36M | 448.10M | 414.42M |
| Gross Profit | 251.40M | 301.24M | 424.74M | 391.70M | 420.53M | 394.32M |
| EBITDA | -611.09M | -572.35M | -1.23B | -775.59M | -390.75M | -110.03M |
| Net Income | -651.85M | -632.09M | -1.29B | -812.41M | -429.69M | -149.00M |
Balance Sheet | ||||||
| Total Assets | 1.97B | 2.17B | 1.67B | 2.37B | 2.96B | 2.46B |
| Cash, Cash Equivalents and Short-Term Investments | 1.54B | 1.71B | 1.13B | 1.87B | 2.33B | 1.93B |
| Total Debt | 594.17M | 605.18M | 797.98M | 885.12M | 967.69M | 340.00M |
| Total Liabilities | 654.26M | 734.01M | 935.57M | 1.09B | 1.08B | 427.72M |
| Stockholders Equity | 1.31B | 1.44B | 733.87M | 1.28B | 1.86B | 2.01B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -496.54M | -1.31B | -601.76M | -364.58M | -179.21M |
| Operating Cash Flow | 0 | -493.79M | -1.30B | -586.82M | -354.77M | -176.31M |
| Investing Cash Flow | 0 | -2.45M | -10.01M | -15.25M | -139.89M | -111.15M |
| Financing Cash Flow | 0 | 1.08B | 567.63M | 134.47M | 867.30M | -104.46M |
D.Western Therapeutics Institute Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4576, the sentiment is Negative. The current price of 59.00 is below the 20-day moving average (MA) of 67.00, below the 50-day MA of 76.06, and below the 200-day MA of 85.10, indicating a bearish trend. The MACD of -4.07 indicates Positive momentum. The RSI at 23.71 is Positive, neither overbought nor oversold. The STOCH value of 11.11 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4576.
D.Western Therapeutics Institute Peers Comparison
Overall Rating
JP:459348Neutral
JP:459243Neutral- JP:457643Neutral
JP:497842Neutral
JP:459938Underperform
JP:777626Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| JP:4593 | 48Neutral | JPY 37.00B | 55.04 | ― | ― | -47.32% | ― |
| JP:4592 | 43Neutral | JPY 71.58B | -19.22 | -37.79% | ― | ― | 5.71% |
| JP:4576 | 43Neutral | JPY 3.40B | -4.96 | -45.41% | ― | -41.25% | 55.11% |
| JP:4978 | 42Neutral | JPY 13.03B | -26.58 | ― | ― | -18.71% | -246.54% |
| JP:4599 | 38Underperform | JPY 8.71B | -4.68 | ― | ― | ― | 4.85% |
| JP:7776 | 26Underperform | JPY 7.43B | -6.49 | ― | ― | -56.16% | 3.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4576 | D.Western Therapeutics Institute, Inc. | 59.00 | -47.00 | -44.34% | |
| JP:4592 | SanBio Co | 917.00 | -1913.00 | -67.60% | |
| JP:4593 | Healios KK | 273.00 | -221.00 | -44.74% | |
| JP:4599 | StemRIM Inc. | 139.00 | -134.00 | -49.08% | |
| JP:4978 | ReproCELL Inc. | 122.00 | -51.00 | -29.48% | |
| JP:7776 | CellSeed Inc. | 188.00 | -249.00 | -56.98% |
D.Western Therapeutics Institute Corporate Events
D. Western Therapeutics Outlines Q2 FY12/26 Results and Outlook
D. Western Therapeutics Institute has released briefing materials for its second quarter results for the fiscal year ending December 2026. The documents outline financial performance, progress in business activities, and an updated forecast for the f...
D.Western Therapeutics Posts Deeper Losses, Keeps 2026 Outlook Unchanged
D.Western Therapeutics Institute reported consolidated net sales of ¥33 million for the first half of 2026, an 80.9% year-on-year decline, with an operating loss of ¥312 million and a net loss attributable to owners of the parent of ¥3...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 16, 2026